THE EARLY BENEFIT ASSESSMENT OF DRUGS THAT ARE LAUNCHED BEFORE 2011

被引：0
|
作者：
Weber, B. [1 ]
机构：
[1] Pfizer, Berlin, Germany
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 07期
关键词：
D O I：
10.1016/j.jval.2012.08.694
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A315 / A316
页数：2
相关论文
共 50 条
  • [1] Early benefit assessment of new drugs in Germany - Results from 2011 to 2012
    Hoern, Helmut
    Nink, Katrin
    McGauran, Natalie
    Wieseler, Beate
    HEALTH POLICY, 2014, 116 (2-3) : 147 - 153
  • [2] Early Benefit Assessment of Drugs and the scientific Medicine
    Selbmann, H. -K.
    NERVENARZT, 2016, 87 (04): : 353 - 354
  • [3] Early Benefit Assessment for new Drugs 2021
    Zielke, R.
    UROLOGE, 2022, 61 (02): : 223 - 223
  • [4] REPURPOSED DRUGS LAUNCHED UNDER THE AMNOG IN GERMANY: EFFECTS ON BENEFIT ASSESSMENT AND PRICE DEVELOPMENT
    Sake, S. M.
    Martyniszyn-Eiben, A.
    Zavatta, E.
    Gluesen, M.
    Berger, I
    Schoenermark, M.
    VALUE IN HEALTH, 2022, 25 (12) : S261 - S261
  • [5] Interplay between marketing authorization and early benefit assessment of drugs
    Beinlich, Peggy
    Mueller-Berghaus, J.
    Sudhop, T.
    Vieths, S.
    Broich, K.
    BUNDESGESUNDHEITSBLATT-GESUNDHEITSFORSCHUNG-GESUNDHEITSSCHUTZ, 2015, 58 (03) : 227 - 231
  • [6] Benefit assessment of drugs
    Kaiser, Thomas
    Vervoelgyi, V.
    Wieseler, B.
    BUNDESGESUNDHEITSBLATT-GESUNDHEITSFORSCHUNG-GESUNDHEITSSCHUTZ, 2015, 58 (03) : 232 - 239
  • [7] Assessment of Price and Clinical Benefit of Cancer Drugs in Canada, 2011-2020
    Jenei, Kristina
    Meyers, Daniel
    Gyawali, Bishal
    JAMA NETWORK OPEN, 2023, 6 (01) : e2253438
  • [8] THIRD PARTY PARTICIPATION IN EARLY BENEFIT ASSESSMENT OF CANCER DRUGS IN GERMANY
    Schmidt, U.
    VALUE IN HEALTH, 2014, 17 (07) : A662 - A662
  • [9] A decade of early benefit assessment of ophthalmic drugs in Germany: success story or not?
    Dintsios, Charalabos-Markos
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022, 22 (02) : 283 - 297
  • [10] Challenges for clinical trials in oncology within the scope of early benefit assessment of drugs
    Lange, Stefan
    ZEITSCHRIFT FUR EVIDENZ FORTBILDUNG UND QUALITAET IM GESUNDHEITSWESEN, 2015, 109 (06): : 417 - 430
12345